The American Diabetes Association and Abbott Collaborate on First-of-Its-Kind Therapeutic Nutrition Program for People With Diabetes

ARLINGTON, VA and ABBOTT PARK, IL / ACCESSWIRE / June 28, 2023 / Abbott:

Abbott

On June 24, the American Diabetes Association^® (ADA) and Abbott announced a collaboration aimed at better understanding how diabetes technology like continuous glucose monitoring (CGM) systems can help people living with diabetes make informed decisions about their food and activity.

Dietary habits play a pivotal role in glucose control. Nonetheless, individual variations in glycemic response to the same foods make it very challenging to prescribe a universal nutritional plan for diabetes management. Clinical studies support that keeping glucose levels steady over time leads to better clinical outcomes for people with diabetes.¹ CGM systems, like those made by Abbott, are an important tool in helping a person manage their diabetes. They offer personalized, real-time data on how food and activity affect glucose levels. Over time, research shows that the data from CGMs allows people with diabetes to learn patterns and create a nutritional plan that provides steady glucose levels and the potential for improved clinical outcomes, like lowering A1C.

"What people with diabetes eat is a critical part of managing their diabetes," said Charles "Chuck" Henderson, chief executive officer of the ADA. "Personalized nutrition using CGMs has the potential to revolutionize diabetes management by providing individuals with more data and tools to manage their glucose levels, improve their quality of life, and reduce the risk of diabetes-related complications. The ADA is grateful to Abbott for its continued support of our mission to improve the lives of people impacted by diabetes. "

For more than 20 years, Abbott and the ADA have worked together with a shared mission to fight for all those affected by diabetes. Abbott is providing a $2.65 million grant over the next three years to the ADA to enable them to:

• Engage with top healthcare professionals and key opinion leaders to evaluate existing clinical evidence on the use of CGM systems for personalized, therapeutic nutrition.
• Launch two pilot programs targeted at adults with Type 2 diabetes to gain a deeper understanding of the role a CGM can play in personalized therapeutic nutrition. These programs will leverage CGM data to understand how they help people with diabetes achieve their objectives, which include modifications to their nutritional intake and dietary habits.
• Host roundtable discussions in collaboration with renowned health care experts to review and evaluate the existing clinical evidence. These discussions will investigate the role of therapeutic nutrition using CGM data and its potential to inform nutrition recommendations.

"Abbott's FreeStyle Libre technology can be a critical tool for all people living with diabetes, not only those on insulin," said Robert B. Ford, chairman and chief executive officer, Abbott. "We look forward to working with the American Diabetes Association to gather further evidence to show how the technology we designed to be affordable and accessible can provide personalized insights t0 help people make informed decisions about their food and activity."

So handeln Sie das Kursziel

Der Analyst erwartet ein Kursziel von 105,32$, was einem Rückgang von -2,06% zum aktuellen Kurs entspricht. Mit diesen Produkten können Sie die Kurserwartungen des Analysten übertreffen.

 

Vontobel

 

Alle Partner

Übernehmen

Für Ihre Einstellungen haben wir keine weiteren passenden Produkte gefunden.
Bitte verändern Sie Kursziel, Zeitraum oder Emittent.Alternativ können Sie auch unsere Derivate-Suchen verwenden
Knock-Out-Suche | Optionsschein-Suche | Zertifikate-Suche

WerbungDisclaimer